Category - Executive Moves

Executive Moves

NY investment community veteran, Miranda Toledano, joins HCW in Israel

Miranda Toledano has joined H.C. Wainwright's healthcare investment banking team where she will focus on building out the firm's footprint across Europe and Israel.

February 15, 2018

Executive Moves

Eiger BioPharma names Eldon Mayer to board

Eiger BioPharmaceuticals (NASDAQ:EIGR) appointed Eldon Mayer as a director, while Chuck Bramlage has left the board to focus on a newly accepted position as CEO at another start-up company.

January 8, 2018

Executive Moves

Ortho RTi names Sharon Ludlow as a director

Ortho Regenerative Technologies (CSE:ORTH) appointed Sharon Ludlow to the board, succeeding Laurence Rulleau, who has resigned.

January 8, 2018

Executive Moves

Eiger BioPharma names Dr. David Apelian as COO, EMO

Eiger BioPharmaceuticals (NASDAQ:EIGR) appointed Dr. David Apelian as chief operating officer and executive medical officer.

January 3, 2018

Executive Moves

Analysts start Quanterix at OP, buy; PTs $27, $26

Analysts at Leerink and BTIG launched coverage of Quanterix (NASDAQ:QTRX) with “outperform” and “buy” ratings, respectively, and price targets of $27 and $26, respectively. The stock closed at $21.47 on Dec. 29.

January 2, 2018

Executive Moves

Ortho RTi appoints Dr. Jacques Toueg to SAB

Ortho Regenerative Technologies (CSE:ORTH) appointed Dr. Jacques Toueg to its scientific advisory board (SAB).

December 19, 2017

Executive Moves

Rubius Therapeutics names Andrew Oh as CFO

Closely-held Rubius Therapeutics appointed Andrew Oh, who has more than 20 years of experience in finance and the biopharmaceutical industry, as CFO.

December 18, 2017

Executive Moves

Vital Therapies names Russell Cox as CEO

Vital Therapies (NASDAQ:VTL) has appointed Russell Cox as CEO and a member of the board, effective January 3, 2018.

December 5, 2017

Executive Moves

Jesse Ledger named CEO of Nuvo Pharma

Nuvo Pharmaceuticals (TSX:NRI) appointed Jesse Ledger as CEO, succeeding John London who continues as executive chairman and a director.

November 23, 2017

Executive Moves

Novelion Therapeutics CEO Mary Szela resigns

Novelion Therapeutics (NASDAQ:NVLN) CEO, Mary Szela, has resigned for personal reasons, effective immediately, and the company has begun a search for a new CEO.

November 9, 2017

Category - Executive Moves

NY investment community veteran, Miranda Toledano, joins HCW in Israel

Eiger BioPharma names Eldon Mayer to board

Ortho RTi names Sharon Ludlow as a director

Eiger BioPharma names Dr. David Apelian as COO, EMO

Analysts start Quanterix at OP, buy; PTs $27, $26

Ortho RTi appoints Dr. Jacques Toueg to SAB

Rubius Therapeutics names Andrew Oh as CFO

Vital Therapies names Russell Cox as CEO

Jesse Ledger named CEO of Nuvo Pharma

Novelion Therapeutics CEO Mary Szela resigns

General

More